NCT01436253
- Conditions
- Dyslipidemia, Dyslipidemias, Lipid Metabolism Disorders, +2 more
- Locations
-
Not specified
Clinical trial condition
Dyslipidemia
Explore clinical trials studying Dyslipidemia. Study availability and eligibility vary by location and protocol.
389 public trials
26 recruiting studies
Dyslipidemia trial results
NCT03203915
- Conditions
- Body Weight, Dyslipidemia, Dyslipidemias, +9 more
- Locations
-
- Western Human Nutrition Research Center Davis, California, United States
NCT04155645
- Conditions
- Dyslipidemia, Dyslipidemias, Lipid Metabolism Disorders, +2 more
- Locations
-
- Research Site Chula Vista, California, United States
- Research Site Glendale, California, United States
- Research Site La Mesa, California, United States
- Research Site Jacksonville, Florida, United States
NCT03267329
- Conditions
- Cardiovascular Diseases, Dyslipidemia, Dyslipidemias, +5 more
- Locations
-
- Seoul National University Hospital Seoul, South Korea
NCT01262638
- Conditions
- Dyslipidemia, Dyslipidemias, Lipid Metabolism Disorders, +2 more
- Locations
-
- Chandler, Arizona, United States
- Greenbrae, California, United States
- Santa Rosa, California, United States
- Jacksonville, Florida, United States
Completed
Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
NCT00673660
- Conditions
- Behavior, Dyslipidemia, Dyslipidemias, +7 more
- Locations
-
- Pfizer Investigational Site Mecidiyeköy, Istanbul, Turkey (Türkiye)
- Pfizer Investigational Site Bolu, Turkey (Türkiye)
- Pfizer Investigational Site Haseki/Istanbul, Turkey (Türkiye)
- Pfizer Investigational Site Istanbul, Turkey (Türkiye)
NCT01304641
- Conditions
- Cardiovascular, Dyslipidemia, Dyslipidemias, +3 more
- Locations
-
Not specified
NCT01243138
- Conditions
- Behavior, Body Weight, Cardiovascular Diseases, +17 more
- Locations
-
- Pfizer Investigational Site Algiers, Algeria
- Pfizer Investigational Site Bejaja, Algeria
- Pfizer Investigational Site Djelfa, Algeria
- Pfizer Investigational Site Laghouat, Algeria
NCT00708370
- Conditions
- Dyslipidemia, Dyslipidemias, Lipid Metabolism Disorders, +2 more
- Locations
-
- Pfizer Investigational Site Jitra, Kubang Pasu, Kedah, Malaysia
- Pfizer Investigational Site Kulim, Kedah, Malaysia
- Pfizer Investigational Site Sik, Kedah, Malaysia
- Pfizer Investigational Site Kubang Kerian, Kelantan, Malaysia
Completed
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
NCT00442325
- Conditions
- Arterial Occlusive Diseases, Arteriosclerosis, Brain Diseases, +23 more
- Locations
-
- Pfizer Investigational Site Ioannina, Greece
- Pfizer Investigational Site Kallithea, Athens, Greece
- Pfizer Investigational Site Pireaus, Greece
- Pfizer Investigational Site Thessaloniki, Greece